RayKnowChina Research Map
Shortlist

Cancer

Lung cancer in Beijing

北京 肺癌

All diseases in Beijing

20 hospitals in Beijing

Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for lung cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Beijing may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 587 papers led
  2. 213 papers led
  3. 176 papers led
    No open trial led
  4. 161 papers led
  5. 102 papers led
  6. 80 papers led
  7. 74 papers led
    No open trial led
  8. 66 papers led
  9. 56 papers led
  10. 53 papers led
  11. 51 papers led
  12. 47 papers led
    No open trial led
  13. 38 papers led
    No open trial led
  14. 34 papers led
    No open trial led
  15. 32 papers led
    No open trial led
  16. 32 papers led
  17. 26 papers led
  18. 18 papers led
    No open trial led
  19. 9 papers led
    No open trial led
  20. 0 papers led

Lung cancer in every city Beijing on the disease page, with the national map

226

open trials on lung cancer with a hospital in Beijing

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Beijing as lead sponsor or study site. 95 of them are led by a hospital in Beijing. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07039474

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First HospitalBeijing

  2. Recruiting
    A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
    Phase
    Phase 2/Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07063745

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Wuhan, Xiamen

  3. Recruiting
    A Study of DXC014 in Patients With Advanced Solid Tumors.
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07177937

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Qingdao

  4. Recruiting
    Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07195695

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou

  5. Recruiting
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07222566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  6. Recruiting
    Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07227298

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Shanghai, Taizhou, Wuhan

  7. Recruiting
    A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07227597

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiangmen, Nanchang, Shanghai, Taizhou

  8. Recruiting
    This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07249879

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  9. Recruiting
    Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07288177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Nanjing, Shanghai, Tianjin, Zhengzhou

  10. Recruiting
    Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07329322

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  11. Recruiting
    First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07332858

    Age 18 years to 75 years (registered criteria)

    Led by China-Japan Friendship HospitalBeijing

  12. Recruiting
    A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07354711

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  13. Recruiting
    A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07361497

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shantou, Shenzhen, Suzhou, Taiyuan, Taizhou, Xi'an, Zhengzhou

  14. Recruiting
    Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07361705

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Shenyang, Taiyuan, Zhengzhou

  15. Recruiting
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07367529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan

  16. Recruiting
    YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer
    Phase
    N/A
    Started
    2026-12
    Posted
    Registry
    NCT07390565

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  17. Recruiting
    A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07413042

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  18. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  19. Recruiting
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07416695

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  20. Recruiting
    MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07431827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanning, Shanghai, Shijiazhuang, Urumqi, Wuhan

  21. Recruiting
    An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07452003

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  22. Recruiting
    A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07459751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  23. Recruiting
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07472517

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou

  24. Recruiting
    Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07476287

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Wuhan, Zhengzhou

  25. Recruiting
    A Retrospective Real-World Study Based on RATIONALE-307
    Phase
    Not given
    Started
    2026-02
    Posted
    Registry
    NCT07478809

    Age not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  26. Recruiting
    Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
    Phase
    Not given
    Started
    2026-03
    Posted
    Registry
    NCT07487883

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  27. Recruiting
    Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07489066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  28. Recruiting
    Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07492342

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou

  29. Recruiting
    A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07541170

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changchun, Chengdu, Foshan, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Shenzhen, Suzhou, Taizhou, Tianjin

  30. Recruiting
    A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07554339

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen

  31. Recruiting
    18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07557225

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  32. Recruiting
    A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07586202

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin

  33. Recruiting
    A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07622186

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shenyang, Taiyuan, Tianjin, Xi'an, Xiamen, Xiangyang, Zhengzhou

  34. Recruiting
    Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07622706

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  35. Recruiting
    Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07668037

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  36. Recruiting
    Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
    Phase
    Not given
    Started
    2026-07
    Posted
    Registry
    NCT07681245

    Age 18 years to 90 years (registered criteria)

    Led by Shanghai Chest Hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  37. Recruiting
    A Study of DS-3939a in Participants With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07739966

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou

  38. Recruiting
    68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07760012

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  39. Recruiting
    Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
    Phase
    Phase 3
    Started
    2026-08
    Posted
    Registry
    NCT07778316

    Age 18 years to 99 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  40. Recruiting
    Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07806604

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  41. Recruiting
    Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07848243

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  42. Recruiting
    MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07894458

    Age 18 years to 85 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  43. Recruiting
    Nectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT05321316

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  44. Recruiting
    A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT06674252

    Age 65 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  45. Recruiting
    Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06712316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou

  46. Recruiting
    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06712355

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  47. Recruiting
    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06758401

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou

  48. Recruiting
    Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06768307

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  49. Recruiting
    Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06780098

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Zhengzhou

  50. Recruiting
    A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06780137

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanjing, Shanghai

  51. Recruiting
    A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06792552

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang

  52. Recruiting
    A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06793215

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nantong, Shanghai, Shantou, Wuhan

  53. Recruiting
    Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06801834

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  54. Recruiting
    Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06809764

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou

  55. Recruiting
    A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06829459

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  56. Recruiting
    Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06849167

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  57. Recruiting
    A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT06855771

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Linyi, Nanchang, Nanning, Taizhou, Xiamen

  58. Recruiting
    The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06861543

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  59. Recruiting
    Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06862869

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi

  60. Recruiting
    Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06869239

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  61. Recruiting
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06875310

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou

  62. Recruiting
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06890598

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an

  63. Recruiting
    A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06892548

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Xi'an, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yichang, Zhengzhou

  64. Recruiting
    Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06895031

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  65. Recruiting
    Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT06897046

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  66. Recruiting
    Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06899126

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  67. Recruiting
    Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06902350

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changchun

  68. Recruiting
    A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06907615

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  69. Recruiting
    Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT06926140

    Age 18 years to 75 years (registered criteria)

    Led by Guang'anmen Hospital; 1 listed hospital as study siteBeijing, Hefei

  70. Recruiting
    A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06930794

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou

  71. Recruiting
    Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT06930807

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  72. Recruiting
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06962865

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou

  73. Recruiting
    A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06969612

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  74. Recruiting
    A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07010263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi

  75. Recruiting
    Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07014202

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  76. Recruiting
    A Study of SKB518 in Patients With Lung Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07019675

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenzhen, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xiangyang, Zhengzhou

  77. Recruiting
    A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT07026669

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  78. Recruiting
    Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT07057102

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  79. Recruiting
    Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07058948

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteBeijing, Tianjin

  80. Recruiting
    Study of GV20-0251 in Participants With Solid Tumor Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07070518

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  81. Recruiting
    Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07079475

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Tianjin

  82. Recruiting
    Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT07087223

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 7 listed hospitals as study sitesBeijing, Dalian, Shijiazhuang, Tianjin

  83. Recruiting
    Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07110103

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 1 listed hospital as study siteBeijing, Chongqing

  84. Recruiting
    Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07120282

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  85. Recruiting
    A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07144280

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi'an, Xuzhou, Zhengzhou

  86. Recruiting
    Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07154706

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou

  87. Recruiting
    A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07164170

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou

  88. Recruiting
    Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT07166003

    Age 18 years to 79 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  89. Recruiting
    A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07174908

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou

  90. Recruiting
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07182682

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou

  91. Recruiting
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07185997

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou

  92. Recruiting
    A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07190248

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  93. Recruiting
    IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07198841

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Foshan, Guangzhou, Nanchang, Nanning, Shijiazhuang

  94. Recruiting
    A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07217301

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou

  95. Recruiting
    A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07218146

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  96. Recruiting
    A Study of Ivonescimab in First-Line ES-SCLC
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07245446

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai, Xi'an

  97. Recruiting
    Application of Methylation Markers in Early Detection and MRD Monitoring of Lung Cancer
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT07257458

    Age 18 years to 85 years (registered criteria)

    Led by Beijing Haidian HospitalBeijing

  98. Recruiting
    Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07257471

    Age 18 years to 85 years (registered criteria)

    Led by Beijing Haidian HospitalBeijing

  99. Recruiting
    To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT07291921

    Age 18 years to 85 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  100. Recruiting
    68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07331532

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  101. Recruiting
    Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
    Phase
    Not given
    Started
    2025-07
    Posted
    Registry
    NCT07359040

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  102. Recruiting
    A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07362940

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Jinan, Xiamen, Zhengzhou

  103. Recruiting
    An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07371663

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Zhengzhou

  104. Recruiting
    Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07443397

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  105. Recruiting
    FAP-targeted PET/NIR in Lung Malignant Tumors
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07498933

    Age 18 years to 70 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  106. Recruiting
    68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07508852

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  107. Recruiting
    Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07586826

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  108. Recruiting
    Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06128837

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  109. Recruiting
    A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2024-01
    Posted
    Registry
    NCT06179069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xi'an, Xiamen, Zhengzhou

  110. Recruiting
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06203210

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou

  111. Recruiting
    Serplulimab Combined With CCRT for LS-SCLC.
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06295926

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  112. Recruiting
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06300177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  113. Recruiting
    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
    Phase
    Phase 3
    Started
    2024-04
    Posted
    Registry
    NCT06312137

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Taizhou, Wuhan, Xi'an, Zhengzhou

  114. Recruiting
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06345729

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou

  115. Recruiting
    ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06388031

    Age 18 years to 80 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  116. Recruiting
    JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06416410

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi'an, Zhengzhou

  117. Recruiting
    A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06421298

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Chest HospitalBeijing

  118. Recruiting
    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
    Phase
    Phase 3
    Started
    2024-06
    Posted
    Registry
    NCT06422143

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou

  119. Recruiting
    Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06440057

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  120. Recruiting
    A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06452277

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Shanghai, Taizhou, Wuhan, Xiamen

  121. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  122. Recruiting
    Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06467617

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Chest HospitalBeijing

  123. Recruiting
    A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06496490

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Jiangmen, Nanchang, Nanning, Shanghai, Tianjin, Xi'an, Zhengzhou, Zunyi

  124. Recruiting
    A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06512051

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  125. Recruiting
    Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
    Phase
    Not given
    Started
    2024-06
    Posted
    Registry
    NCT06518655

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Foshan, Guangzhou, Shanghai, Wuhan

  126. Recruiting
    A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
    Phase
    Phase 3
    Started
    2024-10
    Posted
    Registry
    NCT06561386

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Xinxiang

  127. Recruiting
    A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
    Phase
    Phase 3
    Started
    2024-11
    Posted
    Registry
    NCT06564324

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  128. Recruiting
    A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06581419

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  129. Recruiting
    Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06596915

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  130. Recruiting
    Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT06644430

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  131. Recruiting
    Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06648317

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  132. Recruiting
    Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06674343

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  133. Recruiting
    The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06692972

    Age 18 years to Not stated (registered criteria)

    Led by China-Japan Friendship Hospital; 1 listed hospital as study siteBeijing, Wuhan

  134. Recruiting
    Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
    Phase
    Phase 1
    Started
    2024-06
    Posted
    Registry
    NCT06813365

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  135. Recruiting
    Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06926179

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 2 listed hospitals as study sitesBeijing, Kunming

  136. Recruiting
    Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
    Phase
    Phase 3
    Started
    2024-11
    Posted
    Registry
    NCT06956001

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan

  137. Recruiting
    Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT07433283

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Haikou, Harbin, Shanghai, Zhengzhou

  138. Recruiting
    Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT07632664

    Age 65 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  139. Recruiting
    Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2023-04
    Posted
    Registry
    NCT05786924

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Jinan, Shanghai, Suzhou

  140. Recruiting
    LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2023-05
    Posted
    Registry
    NCT05886439

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  141. Recruiting
    A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05913089

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang

  142. Recruiting
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05920356

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou

  143. Recruiting
    A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06010329

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou

  144. Recruiting
    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT06095583

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou

  145. Recruiting
    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06119581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiangyang, Yichang, Zhanjiang

  146. Recruiting
    COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
    Phase
    N/A
    Started
    2023-12
    Posted
    Registry
    NCT06168032

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  147. Recruiting
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06170788

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou

  148. Recruiting
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2022-03
    Posted
    Registry
    NCT04928846

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  149. Recruiting
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05168566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou

  150. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Posted
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  151. Recruiting
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
    Phase
    Phase 1/Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT05288205

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou

  152. Recruiting
    Multiomics Tumor Evolution Model of NSCLC
    Phase
    Not given
    Started
    2022-04
    Posted
    Registry
    NCT05352035

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  153. Recruiting
    JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05490472

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changchun, Jinan

  154. Recruiting
    A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
    Phase
    Not given
    Started
    2022-05
    Posted
    Registry
    NCT05498064

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  155. Recruiting
    Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05536505

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Qingdao, Shanghai, Shenzhen, Wuhan, Xiamen, Zhongshan

  156. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  157. Recruiting
    A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
    Phase
    Phase 1/Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT07231068

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Zhengzhou

  158. Recruiting
    Research on Early Screening and Diagnosis of Pulmonary Nodules Based on Novel Non-invasive Technologies.
    Phase
    Not given
    Started
    2022-12
    Posted
    Registry
    NCT07370077

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  159. Recruiting
    Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
    Phase
    Phase 1
    Started
    2021-07
    Posted
    Registry
    NCT04886804

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou

  160. Recruiting
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04930432

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  161. Recruiting
    A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-12
    Posted
    Registry
    NCT04996121

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  162. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Shanghai, Shenyang, Taiyuan, Tianjin, Zhengzhou, Zhuhai

  163. Recruiting
    First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 1/Phase 2
    Started
    2021-10
    Posted
    Registry
    NCT05099172

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Taizhou

  164. Recruiting
    A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2021-10
    Posted
    Registry
    NCT05104788

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  165. Recruiting
    Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)
    Phase
    N/A
    Started
    2021-11
    Posted
    Registry
    NCT05559645

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  166. Recruiting
    Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2021-12
    Posted
    Registry
    NCT05751018

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  167. Recruiting
    Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
    Phase
    N/A
    Started
    2020-04
    Posted
    Registry
    NCT04209218

    Age 50 years to 90 years (registered criteria)

    Led by Peking University First HospitalBeijing

  168. Recruiting
    A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
    Phase
    Phase 3
    Started
    2020-07
    Posted
    Registry
    NCT04316364

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Zhengzhou

  169. Recruiting
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
    Phase
    Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04557449

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Wuhan, Xi'an, Zhengzhou

  170. Recruiting
    Study of PF-07248144 in Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2020-11
    Posted
    Registry
    NCT04606446

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Xi'an

  171. Recruiting
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
    Phase
    Phase 2/Phase 3
    Started
    2020-12
    Posted
    Registry
    NCT04613596

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  172. Recruiting
    APG-2449 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2019-05
    Posted
    Registry
    NCT03917043

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Wuhan

  173. Recruiting
    Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2019-07
    Posted
    Registry
    NCT04270591

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  174. Recruiting
    Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
    Phase
    Not given
    Started
    2019-11
    Posted
    Registry
    NCT06255197

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  175. Recruiting
    Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06950697

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Chao-Yang Hospital; 2 listed hospitals as study sitesBeijing, Zhengzhou

  176. Not yet recruiting
    Clinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung Cancer
    Phase
    N/A
    Started
    2027-01
    Posted
    Registry
    NCT07928882

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  177. Not yet recruiting
    A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07307443

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  178. Not yet recruiting
    A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07338396

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Guangzhou

  179. Not yet recruiting
    Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07357532

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  180. Not yet recruiting
    Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07381543

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  181. Not yet recruiting
    IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07402070

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  182. Not yet recruiting
    Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07486648

    Age 18 years to Not stated (registered criteria)

    Led by Shanxi Cancer Hospital; 1 listed hospital as study siteBeijing, Taiyuan

  183. Not yet recruiting
    Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07551414

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  184. Not yet recruiting
    Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07560358

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  185. Not yet recruiting
    A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07583316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  186. Not yet recruiting
    5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07589101

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  187. Not yet recruiting
    Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07618793

    Age 18 years to 75 years (registered criteria)

    Led by Xuanwu HospitalBeijing

  188. Not yet recruiting
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07623642

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

  189. Not yet recruiting
    Deep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CT
    Phase
    Not given
    Started
    2026-06
    Posted
    Registry
    NCT07647692

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  190. Not yet recruiting
    A Clinical Study GK01 Cell Injection in Subjects With Advanced Lung Cancer
    Phase
    Early phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07673419

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  191. Not yet recruiting
    Video-Assisted Thoracoscopic Surgery Combined With Radiofrequency Ablation Versus VATS Alone for Multiple Primary Lung Cancer
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07819669

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shenzhen

  192. Not yet recruiting
    Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance
    Phase
    Phase 1
    Started
    2026-10
    Posted
    Registry
    NCT07842887

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  193. Not yet recruiting
    A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-11
    Posted
    Registry
    NCT07865910

    Age 18 days to 75 days (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesAnyang, Beijing, Chongqing, Guangzhou, Jinan, Nanning, Qingdao, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou, Zunyi

  194. Not yet recruiting
    MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
    Phase
    N/A
    Started
    2026-11
    Posted
    Registry
    NCT07873086

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  195. Not yet recruiting
    Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07882628

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Chao-Yang Hospital; 4 listed hospitals as study sitesBeijing, Changsha

  196. Not yet recruiting
    MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07885709

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  197. Not yet recruiting
    The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06739421

    Age 18 years to 90 years (registered criteria)

    Led by China-Japan Friendship HospitalBeijing

  198. Not yet recruiting
    Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06780839

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  199. Not yet recruiting
    Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06784206

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  200. Not yet recruiting
    Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06885840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou

  201. Not yet recruiting
    Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
    Phase
    Phase 4
    Started
    2025-04
    Posted
    Registry
    NCT06931145

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  202. Not yet recruiting
    Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT06998719

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  203. Not yet recruiting
    Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07004712

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  204. Not yet recruiting
    A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07083375

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  205. Not yet recruiting
    A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07086326

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai, Xi'an

  206. Not yet recruiting
    Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07135297

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest Hospital; 4 listed hospitals as study sitesBeijing, Nanjing, Ningbo, Shanghai, Zhengzhou

  207. Not yet recruiting
    High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07182708

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  208. Not yet recruiting
    Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07200154

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  209. Not yet recruiting
    A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07200947

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  210. Not yet recruiting
    Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07242274

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  211. Not yet recruiting
    A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06254599

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  212. Not yet recruiting
    A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06524518

    Age 18 years to 80 years (registered criteria)

    Led by Xuanwu HospitalBeijing

  213. Not yet recruiting
    Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06752408

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  214. Not yet recruiting
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05767892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  215. Not yet recruiting
    Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer
    Phase
    N/A
    Started
    2023-06
    Posted
    Registry
    NCT05802654

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  216. Not yet recruiting
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05990127

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou

  217. Not yet recruiting
    A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06142617

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  218. Not yet recruiting
    The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer
    Phase
    N/A
    Started
    2022-06
    Posted
    Registry
    NCT05411809

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  219. Enrolling by invitation
    Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07373899

    Age not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  220. Enrolling by invitation
    Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
    Phase
    Not given
    Started
    2025-11
    Posted
    Registry
    NCT07373951

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  221. Enrolling by invitation
    Spontaneous Breathing Mode: A Risk for Hypoxemia During OLV?
    Phase
    Not given
    Started
    2025-07
    Posted
    Registry
    NCT07494006

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  222. Enrolling by invitation
    LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT06876675

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  223. Enrolling by invitation
    ⁶⁸Ga-DPA in the Lung Cancer Diagnosis
    Phase
    Early phase 1
    Started
    2024-09
    Posted
    Registry
    NCT07023068

    Age 18 years to 85 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  224. Enrolling by invitation
    Application of Generative Artificial Intelligence in Perioperative Personalized Rehabilitation for Older Adults With Lung Cancer
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT07915193

    Age 65 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  225. Enrolling by invitation
    Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
    Phase
    Phase 3
    Started
    2021-08
    Posted
    Registry
    NCT04762459

    Age 18 years to 130 years (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

  226. Enrolling by invitation
    FHND9041 Versus Afatinib for Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2021-08
    Posted
    Registry
    NCT06759857

    Age 18 months to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Beijing

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Beijing, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Aerospace Center Hospital航天中心医院nonenonenonenonenonenonenonenonenonenonenone111nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone332none0nonenonenonenonenonenone1nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Air Force General Hospital中国人民解放军空军特色医学中心nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing An Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Anding Hospital首都医科大学附属北京安定医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Anzhen Hospital首都医科大学附属北京安贞医院none6nonenonenonenonenonenonenonenonenone10nonenonenonenonenone2none0nonenonenonenonenone0nonenonenonenone19611 open805 opennonenone30none1nonenonenone0nonenone213nonenonenone1nonenonenonenonenonenonenonenonenonenone
Beijing Army General Hospital中国人民解放军总医院第七医学中心nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Boren Hospital北京高博博仁医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone01nonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Chao-Yang Hospital首都医科大学附属北京朝阳医院none81812662 open1821nonenonenone2601252nonenonenone20none00nonenonenonenonenonenonenone342 open340none3none13none1nonenonenonenone1none4nonenonenone321nonenonenone0nonenonenonenone
Beijing Chest Hospital首都医科大学附属北京胸科医院nonenonenonenone802 opennonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Children's Hospital首都医科大学附属北京儿童医院nonenonenonenonenonenonenonenone46none5none331 open4none49311 open251332012nonenone2none156241743nonenonenone100none11170nonenonenonenonenone131nonenonenone0nonenone
Beijing Daxing District People's Hospital北京市大兴区人民医院nonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Ditan Hospital, Capital Medical University首都医科大学附属北京地坛医院nonenone72nonenonenonenone50nonenonenonenonenonenonenonenonenonenone7nonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenone1nonenonenonenonenonenonenonenonenonenonenonenone110nonenonenonenonenonenonenonenonenone
Beijing Friendship Hospital首都医科大学附属北京友谊医院none12511 open457 open3810401 opennone11none224711nonenone523 open30none0none0nonenone121none41 open4251 open0nonenone2none1nonenonenonenone1none1none02nonenone121 open4none0nonenonenonenonenonenonenone
Beijing Fuwai Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing GoBroad Hospital北京高博医院none01 open01 opennonenonenone01 opennonenonenonenonenonenonenonenone02 open04 opennonenone25 opennonenonenonenonenonenone01 open01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Haidian Hospital北京市海淀医院nonenonenonenone02 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Hospital北京医院nonenone151 open4741025nonenonenonenonenone01none2nonenonenone6none2none0none0none1141 opennonenone303 open3none01none8nonenonenonenonenone02none1nonenonenonenonenonenonenone0nonenonenonenonenonenone
Beijing Hospital, Capital Medical University北京市中西医结合医院nonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenone4nonenonenone11nonenonenonenonenonenonenonenonenone
Beijing Huairou Hospital北京怀柔医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing HuiLongGuan Hospital北京回龙观医院nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Jishuitan Hospital北京积水潭医院nonenonenonenonenonenonenonenonenonenone021nonenone16nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4none0nonenonenone0nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone
Beijing Jishuitan Hospital Guizhou Hospital北京积水潭医院贵州医院nonenonenonenonenonenonenonenonenonenone12nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Jishuitan Hospital Liaocheng Hospital北京积水潭医院聊城医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Lu Daopei Hospital北京道培医院nonenonenonenonenonenonenonenonenonenonenone1nonenone1none1none3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Luhe Hospital首都医科大学附属北京潞河医院nonenonenonenonenone7nonenonenone1none002nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenone
Beijing Rehabilitation Hospital首都医科大学附属北京康复医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Sanbo Brain Hospital北京三博脑科医院nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Shijitan Hospital北京世纪坛医院none191447none28130nonenone1none0nonenonenonenonenone400nonenonenonenonenonenonenonenonenonenonenonenonenone2nonenone1nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Stomatological Hospital首都医科大学附属北京口腔医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone5nonenonenonenonenonenonenonenonenonenonenone
Beijing Tiantan Hospital首都医科大学附属北京天坛医院nonenonenonenone18nonenone30712 opennonenone140none0nonenonenonenonenone242 opennone1nonenonenone342 opennone1609 opennonenone172 opennonenone61none2none40nonenone1nonenonenonenone0nonenonenonenonenonenonenonenone1nonenonenone
Beijing Tongren Hospital首都医科大学附属北京同仁医院61301534814none821none7none91601 opennone11 open357 opennone0nonenonenone736none3none45242 opennonenone1nonenonenonenonenonenone1none2nonenonenone2nonenone1none0none4nonenonenone
Beijing Tsinghua Changgung Hospital北京清华长庚医院nonenone29nonenone4none121002nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone8nonenone010none1none0nonenonenone10nonenonenonenone1nonenonenonenonenonenonenonenonenone
Beijing United Family Hospital北京和睦家医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenone
Beijing Youan Hospital, Capital Medical University首都医科大学附属北京佑安医院nonenone67nonenonenonenonenonenonenonenone1nonenonenonenonenonenone26nonenonenonenonenonenonenonenonenone5nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenone70nonenonenonenonenonenonenonenonenone
Beijng Anzhen Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College中国医学科学院肿瘤医院nonenonenonenone9none4nonenonenonenonenonenonenonenonenonenonenonenone01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Capital Medical University Electric Teaching Hospital北京电力医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Capital Medical University Sanbo Brain Hospital北京三博脑科医院nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children's Hospital, Peking Union Medical College首都医科大学附属首都儿童医学中心nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenone2nonenonenonenone2nonenonenonenone0nonenonenone1nonenonenonenonenonenonenone23nonenonenonenonenonenonenone
China-Japan Friendship Hospital中日友好医院none5none13563 open9nonenonenonenonenone2nonenonenone2nonenone22nonenonenonenonenone60nonenonenonenone262 opennonenone001 opennone190none1100nonenone9nonenonenone10nonenonenonenone0nonenonenonenone
Chinese Medicine Affiliated Shenzhen Hospital北京中医药大学深圳医院(龙岗)nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Chinese Medicine Third Affiliated Hospital北京中医药大学第三附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Chinese PLA General Hospital中国人民解放军总医院8271846 open1406 open176712 open914 open561 open32none1271152 open06 open11 open21 open3730 open011nonenone122 open52 open4461 opennonenone765 open9110023120231601171 open1none02nonenonenonenonenone01nonenonenone
Civil Aviation General Hospital民航总医院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Dongfang Hospital北京中医药大学东方医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone5nonenonenone1none5nonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Dongzhimen Hospital北京中医药大学东直门医院nonenonenonenonenonenonenonenonenonenonenone0none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone7nonenonenonenonenone2none5nonenonenonenonenone14nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Dongzhimen Hospital北京中医药大学东直门医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fangshan Hospital, Beijing University of Chinese Medicine北京市房山区中医医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Jinzhou Medical University锦州医科大学附属第一医院none3none1932none218nonenonenone51nonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone1none0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Hospital of Tsinghua University北京华信医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone10nonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Integrative Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fu Wai Hospital中国医学科学院阜外心血管病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone340nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fu Wai Hospital中国医学科学院阜外心血管病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone21 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fu Wai Hospital, Peking Union Medical College中国医学科学院阜外心血管病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fuwai Hospital中国医学科学院阜外心血管病医院nonenonenonenonenonenonenonenonenonenonenone1none1nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone2432 open1503 opennonenone14nonenonenonenonenone21 opennonenone5nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
FuWai Hospital, Peking Union Medical Collegenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fuxing Hospital首都医科大学附属复兴医院nonenonenonenonenonenonenonenonenonenonenone1none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenone0nonenonenonenonenonenonenonenonenonenone
Guang Anmen Hospital中国中医科学院广安门医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guang'anmen Hospital中国中医科学院广安门医院nonenonenone91 open321 open10122 opennonenonenonenonenone1nonenonenonenonenonenonenone0nonenonenonenonenonenone3nonenonenone20none2nonenonenone1nonenonenonenonenonenonenonenone5nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Medical Sciences Fuwai Hospital中国医学科学院阜外医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
National Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院331 open18410 open1033 open1312 open58725 open452 open33335 open101 opennonenonenone8121nonenone3none832 open1nonenonenone1nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking Union Medical College Fuwai Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking Union Medical College Hospital北京协和医院341 open6510 open5421313 open2279 open10610 open521 opennone0none4671 open1272 open1161 open77410 open11711none8477 open69nonenone294 open16892 open327018144431 open212492 opennone51none14221 open321110nonenone0nonenone
Peking University Aerospace Center Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking University Cancer Hospital北京大学肿瘤医院2826 open425 open2239 open16122 open342 open11614 opennonenonenonenone4121 open123nonenonenone834 opennonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking University First Hospital北京大学第一医院nonenone202 open271 open535 open283 open444 opennone0nonenone41 open261175 opennonenone1366 opennone12nonenone153nonenonenone232 open571 open1114none21811128651 opennone0none01none15none1nonenonenonenone
Peking University International Hospital北大国际医院nonenonenonenonenonenonenonenone1nonenone00nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone6nonenonenone3nonenonenonenonenonenonenonenonenonenonenone2none1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking University People's Hospital北京大学人民医院none2241 open213 open10214 open31 open4422 opennonenone06442 open102 opennone82 open195 open194 open293 open71 open146 opennone01 opennone42 open201 open121 open3nonenonenone1357none1none3nonenonenonenonenonenone51 opennone00none2700nonenonenone0nonenonenonenone
Peking University Shougang Hospital北京大学首钢医院nonenonenonenonenonenonenonenonenonenonenone11none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenone0nonenonenonenonenonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking University Third Hospital北京大学第三医院nonenone121 open262 open514 open162 open282 open232 opennonenone6720070nonenone313 open01none0none22none2nonenone172 open541none102none522 open01 open1none10none1nonenonenone0nonenonenonenonenone0nonenonenonenone
Plastic Surgery Hospital中国医学科学院整形外科医院nonenonenonenonenonenone20nonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Plastic Surgery Hospital, Peking Union Medical Collegenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
PUMC Hospital中国医学科学院北京协和医院nonenonenonenonenone0nonenonenonenonenone00none0nonenone0nonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenone0nonenonenonenonenonenone0nonenonenonenonenonenonenonenone1nonenonenonenonenone
Sanbo Brain Hospital首都医科大学三博脑科医院nonenonenonenonenonenonenone301 opennonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Sanbo Brain Hospital, Capital Medical Universitynonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Artillery General Hospital中国人民解放军火箭军特色医学中心nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shijitan Hospital, Captial Medical University首都医科大学附属北京世纪坛医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Wangjing Hospital中国中医科学院望京医院nonenonenonenonenonenonenonenonenonenonenone2nonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xiyuan Hospital中国中医科学院西苑医院nonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone25nonenonenonenonenone0none1nonenonenonenonenonenone9nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xuanwu Hospital首都医科大学宣武医院2none155262 open61225none071none3nonenone0nonenone71nonenone1none52 open2161 open7nonenone151 open5122 open96nonenonenone7nonenonenone10none2none1nonenonenonenonenonenonenonenonenonenonenonenone
Yuquan Hospital清华大学玉泉医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Beijing.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for lung cancer.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Beijing on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data